Please login to the form below

Not currently logged in
Email:
Password:

Brintellix

This page shows the latest Brintellix news and features for those working in and with pharma, biotech and healthcare.

Lundbeck still feeling effects from Cipralex patent loss

Lundbeck still feeling effects from Cipralex patent loss

Epilepsy treatment Sabril ( vigabatrin) also had a good quarter with sales climbing 42 to 186m krone and Lundbeck also booked 59m krone from antidepressant Brintellix( vortioxetine) in the quarter, although it

Latest news

  • Lundbeck launches <b>Brintellix</b> in first EU market Lundbeck launches Brintellix in first EU market

    Lundbeck launches Brintellix in first EU market. The antidepressant set to sell worldwide. ... Danish pharma company Lundbeck is selling its new antidepressant Brintellix in its home market, the first European launch for the product.

  • EMA backs Lundbeck's <b>Brintellix</b> in depression EMA backs Lundbeck's Brintellix in depression

    EMA backs Lundbeck's Brintellix in depression. Drug recommended for approval to treat major depressive episodes in adults. ... In the latest round of EU drug recommendations, Lundbeck won backing for the use of Brintellix in the treatment of adult

  • Lundbeck buoyed by <b>Brintellix</b> approval in US Lundbeck buoyed by Brintellix approval in US

    Lundbeck buoyed by Brintellix approval in US. FDA gives green light for to Cipralex/Lexapro successor in depression. ... Lundbeck was celebrating yesterday after the FDA approved its new antidepressant Brintellix, a successor to the big-selling

  • Lundbeck and Takeda submit depression drug for US approval Lundbeck and Takeda submit depression drug for US approval

    Lundbeck and Takeda submit depression drug for US approval. Brintellix could help Lundbeck overcome loss of patent protection for Lexapro/Cipralex. ... Lundbeck's plans to find a replacement for its big-selling antidepressant Lexapro/Cipralex continue

  • Pharma spent $342m on journal advertising in first half of 2014 Pharma spent $342m on journal advertising in first half of 2014

    J&J spent $12m to advertise the drug, which was approved in the US in April 2013, was up 84 on the same period in 2013, while Lundbeck's antidepressant Brintellix was

More from news
Approximately 5 fully matching, plus 15 partially matching documents found.

Latest appointments

  • Bayer’s Barbara Jaszewski joins Lundbeck Bayer’s Barbara Jaszewski joins Lundbeck

    In addition, Lundbeck also has Brintellix ( vortioxetine) under review by the EMA, while a once-monthly version of schizophrenia drug Abilify ( aripiprazole) is also due to launch during 2013.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pulsar Healthcare

Pulsar Healthcare is a forward-looking, full-service creative agency, specialising in the pharmaceutical, healthcare and medical device sectors. As such, we...

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...